Moderna’s COVID-19 Second Booster Authorization Largely Thanks To Pfizer/BioNTech Data

 
• By Sue Sutter

Safety and effectiveness of an mRNA-1273 second booster dose was inferred in large part by extrapolation from reported evidence following use of the Pfizer/BioNTech COVID-19 vaccine in individuals 60 years and older in Israel, FDA review memos show.  

Piggy back
Moderna piggybacked on Pfizer/BioNTech's data for a second booster shot. • Source: Alamy

More from Vaccines

More from Pink Sheet